Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
7
Bullish
3
Bearish
11
Neutral
8
Bullish
27
Bearish
7
Neutral
1
Bullish
24
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Trident Lifeline Limited is a rapidly growing pharmaceutical company, specializing in manufacturing and exporting pharmaceutical formulations globally. It operates in several regions, including Africa, Latin America, and Asia.
The company has shown robust financial growth, with a 44% year-over-year revenue increase in Q3FY26. Its EBITDA also surged by 53% in the same period, demonstrating a strong operational performance.
Strategic acquisitions have been pivotal for Trident, acquiring stakes in subsidiaries like TNS Pharma, TLL Parenterals, and Trident Mediquip, enhancing its manufacturing and distribution capabilities.
A hybrid manufacturing model is at the core of Trident's operations, combining in-house manufacturing with contract manufacturing to meet growing demands effectively.
Trident Lifeline is heavily investing in product registrations, with over 3,500 products in the pipeline, which could significantly propel its market presence and revenue growth in the coming years.
Pharmaceuticals & Biotechnology
Pharmaceuticals
313 Cr
Low Risk
16.5
36.7
0.1
3.1
328.00
229.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Trident Lifeline Ltd (TLL) is currently trading at 262.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Trident Lifeline Limited is a rapidly growing pharmaceutical company, specializing in manufacturing and exporting pharmaceutical formulations globally. It operates in several regions, including Africa, Latin America, and Asia. The company has shown robust financial growth, with a 44% year-over-year revenue increase in Q3FY26. Its EBITDA also surged by 53% in the same period, demonstrating a strong operational performance. Strategic acquisitions have been pivotal for Trident, acquiring stakes in subsidiaries like TNS Pharma, TLL Parenterals, and Trident Mediquip, enhancing its manufacturing and distribution capabilities. A hybrid manufacturing model is at the core of Trident's operations, combining in-house manufacturing with contract manufacturing to meet growing demands effectively. Trident Lifeline is heavily investing in product registrations, with over 3,500 products in the pipeline, which could significantly propel its market presence and revenue growth in the coming years.
Over the past 52 weeks, Trident Lifeline Ltd has traded between a low of ₹229.95 and a high of ₹328.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Trident Lifeline Ltd has a market capitalization of approximately 313.30. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Trident Lifeline Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 313.30 Cr, Trident Lifeline Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Trident Lifeline Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Trident Lifeline Ltd is 16.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The company appointed Ms. Smita Kiran Davda and Mr. Sachin Bhandari as Additional Directors in the capacity of Non-Executive Independent Directors with effect from June 13, 2026, subject to shareholder approval.
Discovery themes featuring this stockBoard Meeting
Trident Lifeline Ltd: Board will meet on 2026-07-29 to consider and approve unaudited standalone and consolidated financial results for quarter ended 30 June 2026; trading window closed from 01-07-2026 and reopens 48 hours after results.
Board Meeting
Trident Lifeline Ltd will hold a Board meeting on 2026-07-29 to consider and approve unaudited standalone & consolidated results for quarter ended 30-06-2026. Trading window closed from 01-07-2026 and reopens 48 hours after results are made public.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
594.00 | 340 Cr | 31.42 | 4.49 | 0.85 | 14.04 | 19.30 | 10.92 | ||
243.25 | 328 Cr | 34.06 | 1.19 | 0.41 | 3.50 | 4.79 | 2.63 | ||
60.17 | 327 Cr | — | 1.05 | 0.00 | -1.05 | 0.74 | -0.71 | ||
209.00 | 326 Cr | 26.79 | 2.69 | 0.00 | 10.04 | 16.02 | 8.12 | ||
38.54 | 317 Cr | 24.18 | 4.20 | 0.00 | 17.38 | 20.98 | 8.55 | ||
262.50 | 313 Cr | 16.45 | 3.12 | 0.00 | 18.97 | 18.05 | 8.16 | ||
290.00 | 290 Cr | 52.22 | 3.64 | 0.00 | 7.35 | 11.62 | 2.32 | ||
| Median: 7 Co. | — | 243.25 | 326 Cr | 29.11 | 3.12 | 0.00 | 10.04 | 16.02 | 8.12 |
